NESMOS

Nesmos is a South Korean biotechnology company focused on developing first-in-class small molecule therapeutics for neurodegenerative diseases. The company's research platform centers on the modulation of autophagy and mitophagy, the cellular processes responsible for clearing toxic protein aggregates and damaged mitochondria. By enhancing these natural waste-disposal mechanisms, Nesmos aims to address the underlying pathology of conditions such as Alzheimer's and Parkinson's disease. Their lead program, NM-1001, is a brain-penetrant autophagy enhancer designed to provide neuroprotection and improve cognitive function. Founded as a spin-off from Yonsei University, Nesmos leverages deep expertise in cellular homeostasis to build a robust pipeline of disease-modifying treatments.